ArticleWorld journal of surgical oncology2008
Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
Article in World journal of surgical oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis.PLoS medicine · 2014Pooled it
- Tumor characteristics and survival rate of axillary metastatic breast cancer patients: a three decades retrospective cohort study.Scientific reports · 2025Article
- Clinicopathological Characteristics of Breast Cancer Patients with Equivocal Immunohistochemistry: A Prevalence-Based Statistical Analysis.Iranian journal of pathology · 2025Article
- Article
- Article
- Breast cancer in togolese women: immunohistochemistry subtypes.BMC women's health · 2020Article
- Down Regulation of KAI1/CD82 in Lymph Node Positive and Advanced T-Stage Group in Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Article
- HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women.BMC clinical pathology · 2019Article
- The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian WomanAsian Pacific journal of cancer prevention : APJCP · 2018Article
- First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases.BMC women's health · 2017Article
- Correlation of Hormone Receptor Expression with Histologic Parameters in Benign and Malignant Breast Tumors.Iranian journal of pathology · 2015Article
- Study of hormone receptors and epidermal growth factor expression in invasive breast cancers in a cohort of Western India.Indian journal of clinical biochemistry : IJCB · 2013Article
- Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan.Ecancermedicalscience · 2012Article
- Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.Medical oncology (Northwood, London, England) · 2010Article
- Evaluation of Serum Levels of HER2, MMP-9, Nitric Oxide, and Total Antioxidant Capacity in Egyptian Breast Cancer Patients: Correlation with Clinico-Pathological Parameters.Scientia pharmaceuticaArticle
- Evaluation of grading and hormone receptor immunostaining on fine needle aspirates in carcinoma breast.Journal of cytologyArticle
- Correlation of Hormone Receptor and Human Epidermal Growth Factor Receptor-2/neu Expression in Breast Cancer with Various Clinicopathologic Factors.Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric OncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast carcinoma is a disease with a tremendous heterogeneity in its clinical behavior. Newer prognostic factors and predictors of response to therapy are needed. The aim of this study was to evaluate the expression of HER-2, estrogen receptor (ER) and progesterone receptors (PR) in breast carcinoma and to compare it with other prognostic parameters such as histological type and grade, tumor size, patients' age, and lymph node metastases. PATIENTS AND
methodsThis is a retrospective study conducted in the department of pathology at Sfax University Hospital. Confirmed 155 Cases of breast carcinoma were reviewed in the period between January 2000 and December 2004. We used immunohistochemistry to evaluate the expression of HER-2, ER, and PR receptor and Chi-square and Fisher exact test to correlate immunohistochemical findings with prognostic parameters for breast carcinoma such as patients' age, tumor size, histological type, histological grade and lymph node status.
resultsThe mean age of patients was 51.5 years, ranging from 22 to 89 years. 80 (51.6%) of the patients were below 50 years. The percentage of expression of HER-2, ER and PR was 26, 59.4, and 52.3%, respectively. HER-2 was over-expressed (3+) in 18.1% of the cases, was inversely related to ER expression (p = 0.00) and to PR expression (p = 0.048). This over-expression was also associated with a high tumor grade with marginal significance (p = 0.072). A negative correlation was noted between ER and PR expression and SBR grade (p = 0.000) and ER and age (p = 0.002).
conclusionHER-2 over-expression was observed in 18.1% of Tunisian breast carcinoma affecting female patients. This group presents apparently an aggressive form of breast carcinoma with high histological grade and negative ER.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.